Artrya Limited (ASX:AYA): FY26 Financial Results and Salix Commercialisation Update

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Artrya Limited (ASX:AYA): FY26 Financial Results and Salix Commercialisation Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Artrya Limited (ASX:AYA) reported FY26 revenue of AUD 28,000.
FY26 net loss attributable to owners was AUD 25.183 million.
FY26 operating cash outflow totalled AUD 17.955 million.
The company reported US hospital deployments of its Salix coronary imaging platform.

Artrya Limited develops artificial intelligence-based software to assist clinicians assessing coronary artery disease using cardiac computed tomography images. On 22 October 2026, Artrya Limited (ASX:AYA) was trading at AUD 2.665, up 0.57% during the trading session. Its FY26 reporting and September operational presentation describe the expansion of US commercial deployments, alongside continuing expenditure on software development, clinical validation and sales infrastructure. The stated trading movement is not attributed to those earlier disclosures.

Company Business

Artrya Limited (ASX:AYA) develops and commercialises Salix, a software platform that helps clinicians review coronary computed tomography angiography (CCTA) studies. Its tools visualise coronary anatomy and plaque characteristics to support assessment of coronary artery disease. The software is an adjunct to, rather than a replacement for, clinical judgement. Artrya is based in Western Australia and operates through Australian, US and UK entities, with the United States a particular commercial focus.

The Salix portfolio includes Coronary Anatomy and Coronary Plaque functions, while Coronary Flow is a separate development and regulatory workstream. Its commercial model includes subscription and contracted per-scan fees. Hospital reimbursement amounts referenced in corporate presentations are payments to service providers, not revenue automatically received by Artrya. Commercial uptake therefore depends on actual patient-scanning activity, contracted fees and successful integration with hospital workflows.

Recent Development

In its September 2026 FY26 operational presentation, Artrya Limited (ASX:AYA) identified three contracted US health-system customers: Tanner Health, Northeast Georgia Health System and Cone Health. It reported live Salix use at Tanner and Northeast Georgia, with Cone progressing through deployment. The company also outlined research and clinical validation through its SAPPHIRE programme and continuing regulatory work for Coronary Flow. These are company-reported operational stages, not confirmation that every contracted hospital is fully deployed.

The presentation described Coronary Anatomy and Coronary Plaque as cleared for the US market, while targeting clearance for Coronary Flow by the end of 2026. That target is a company objective rather than an achieved regulatory event. The ability to expand beyond initial sites remains linked to information-system integration, physician training and hospital purchasing and reimbursement processes.

Financial Performance and Sector Context

For the year ended 30 June 2026, Artrya Limited (ASX:AYA) recorded revenue of AUD 28,000. The company reported a net loss attributable to owners of AUD 25.183 million, compared with AUD 16.406 million for FY25. Its FY26 operating loss was AUD 27.600 million, compared with AUD 16.618 million in FY25. The annual results indicate that commercial revenue remained limited relative to development, personnel and market-entry spending.

FY26 net cash used in operating activities was AUD 17.955 million, compared with AUD 14.271 million in FY25. The annual cash-flow statement reported cash and cash equivalents of AUD 44.025 million at 30 June 2026, compared with AUD 11.332 million one year earlier. Financing cash inflows supported the year-end cash position. Cash holdings should be assessed alongside operating outflows and the cost of further commercial deployment.

Artrya Limited (ASX:AYA) operates in a regulated diagnostic-software market where clinical utility must be demonstrated alongside compatibility with existing clinical systems. US commercialisation requires technical deployment, physician adoption and coordination with hospital procurement and payment processes. Regulatory clearance permits relevant marketing activities but does not itself establish usage volumes, recurring revenue or profitability. Reported contracts and live installations are therefore distinct milestones from recognised revenue.

Risks to Consider

The company faces regulatory review risk for products still undergoing clearance, competition from other cardiac-imaging technology providers and potential delays in hospital integration. Operating losses and cash consumption also create funding considerations if commercial receipts develop more slowly than costs. Contracted customers may adopt tools gradually, use fewer scans than anticipated or revise purchasing priorities. Cybersecurity, patient-data handling and software reliability remain relevant operational requirements for clinical applications.

What to Watch Next

Subsequent quarterly cash-flow releases will show whether Artrya Limited (ASX:AYA) can moderate cash use as installations advance. Operational updates may identify additional live hospital sites, utilisation of Coronary Plaque, progress at Cone Health and results from SAPPHIRE clinical work. Any formal FDA decision on Coronary Flow should be assessed against the company’s stated development targets. Financial reports will establish the extent to which deployment milestones translate into recognised sales.

Key Insights

Artrya has moved its Salix platform into reported use at US hospitals, but FY26 audited results show low recognised revenue and a larger annual loss. Its cash resources provide context for ongoing regulatory, clinical and commercial expenditure. The key measurable developments remain hospital utilisation, additional deployment completions, product-clearance outcomes, operating cash requirements and the conversion of contracts into recurring revenue.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.